NEW ORLEANS--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today presented the results from an oral abuse liability study of Acurox® (oxycodone HCl/niacin) Tablets, AP-ADF-111 (Study 111), at the American Society of Addiction Medicine’s (ASAM) Medical-Scientific Conference. The results of Study 111 demonstrate that Acurox® Tablets are disliked among people with a history of opioid abuse compared to oxycodone HC1 tablets alone, when excess doses are swallowed. Dr. Donald R. Jasinski, Chief of the Center for Chemical Dependence of Johns Hopkins Bayview Medical Center, authored the study.
